Formulation and Evaluation of meclofenamate fast dissolving tablet.
The study of this work was to use a swellable polymer chosen among superdisintegrants, for improving the dissolution rate of a sparingly soluble drug, loaded on its surface. Meclofenamate, which has very low water solubility, was chosen as a model drug, while cross linked sodium carboxymethyl cellulose (Ac-Di-Sol) was chosen as the swellable polymer. The Drug Polymer systems were prepared using direct compression method.The results of the dissolution tests showed that the dissolution rate of Meclofenamate from the systems prepared increase, particularly in the case of the preparation composed of Ac-Di-Sol plus surfactant agents. Attempts were made to increase the rate of drug release (disintegration) to enhance the in vitro dissolution of the poorly soluble drug by using extra, intra and partly intra and extra granular method of addition of sodium starch glycolate as superdisintegrants and to develop a stable immediate release formulation by direct compression method.
2. Konapure SA, Chaudhari PS, Oswal RJ, Kshirsagar SS, Antre RV, Chorage TV. “Mouth dissolving tablets” an innovative technology. Int J Appl Biol Pharm Technol. 2011; 2(1):496–503.
3. Karthikeyan M, Umarul MAK, Megha M, Shadeer HP. Formulation of diclofenac tablets for rapid pain relief. Asian Pac J Trop Biomed. 2011; 2(Suppl 1):S308–S311.
4. Kumar S, Gupta SK, Sharma PK. A review on recent trends in oral drug delivery-fast dissolving formulation technology. Adv Biol Res. 2012; 6(1):6–13.
5. Sultan A., Park J. B., Mefenamic acid taste-masked oral disintegrating tablets with enhanced solubility via molecular interaction produced by hot melt extrusion technology, Journal of Drug Delivery Science and Technology, 2015; 27:18–27. 6.
6. Wagstaff AJ and Bryson HM, Meclofenamate Sodium: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with pain and dental pain. Drugs, 1997; 53:435-452.
7. Moffat AC, Clark’s isolation and identification of drugs. London: Pharmaceutical Press; 2006; 691.
8. Acorda Therapeutics, Inc. Meclovate (Meclofenamate Sodium) Tablets and Capsules Prescribing Information. Hawthorne: Acorda Therapeutics; 2006.
9. Moffat AC. Clark’s Isolation and Identification of Drugs. London: Pharmaceutical Press; 2006. Page-691.
10. Setty CM, Prasad DVK, Gupta VRM, Development of fast dispersible aceclofenac tablets: Effect of functionality of superdisintegrants; IJPS, 2008; 70:180–185.
11. Gunda RK, Manchineni PR, Reddy CG, et al. Formulation development and in vitro evaluation of oral disintegrating tablets for newer anticonvulsant agent. J Anal Pharm Res. 2019; 8(2):85‒89.
12. Santosh Kumar R, Kumari A, Fast dissolving tablets: waterless patient compliance dosage forms, Journal of Drug Delivery and Therapeutics. 2019; 9(1):303-317.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).